• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

膀胱过度活动症药理学中的性别差异

Sex and Gender Differences in the Pharmacology of the Overactive Urinary Bladder.

作者信息

Pautz Andrea, Michel Martin C

机构信息

Department of Pharmacology, University Medical Center, Johannes Gutenberg University, Mainz, Germany.

出版信息

Handb Exp Pharmacol. 2023;282:57-74. doi: 10.1007/164_2023_667.

DOI:10.1007/164_2023_667
PMID:37439844
Abstract

Dysfunction of the lower urinary tract in general and the overactive bladder syndrome (OAB) in particular are prevalent and have major impact on the quality of life of the afflicted patients and their partners. We concisely review sex and gender differences in patients and animal models in physiological bladder function, its alterations in disease (mostly OAB), and its responses to treatment. Women appear to have a smaller functional bladder capacity and, therefore, must void more often than men. On the other hand, men have a greater bladder outlet resistance, which is partly attributed to a longer urethra and partly to the presence of the prostate. Sex and gender differences in bladder contractility appear small and were not found consistently. The ability of bladder smooth muscle to relax may be somewhat smaller in females. However, females are heavily underrepresented in experimental studies on bladder function. Stress urinary incontinence is found predominantly in women (particularly those after childbirth). OAB is similarly prevalent in men and women. Females seek treatment much more often and are overrepresented in clinical trials. Treatment responses in OAB patients are similar in both genders for oral medications, but improvements upon injections of onabotulinum toxin type A appear smaller in men. We conclude that there is no evidence for major sex and gender differences in bladder dysfunction as related to OAB and its treatment responses, but female animals are heavily underrepresented in experimental studies.

摘要

下尿路功能障碍,尤其是膀胱过度活动症(OAB),十分普遍,对患病患者及其伴侣的生活质量有重大影响。我们简要回顾了患者和动物模型在生理性膀胱功能方面的性别差异、疾病(主要是OAB)中的功能改变及其对治疗的反应。女性的功能性膀胱容量似乎较小,因此,她们比男性更频繁地排尿。另一方面,男性的膀胱出口阻力更大,部分原因是尿道较长,部分原因是前列腺的存在。膀胱收缩性方面的性别差异似乎较小,且结果并不一致。女性膀胱平滑肌的舒张能力可能稍小。然而,在膀胱功能实验研究中,女性的代表性严重不足。压力性尿失禁主要见于女性(尤其是产后女性)。OAB在男性和女性中同样普遍。女性更常寻求治疗,在临床试验中的代表性过高。口服药物治疗时,OAB患者的治疗反应在两性中相似,但注射A型肉毒杆菌毒素后,男性的改善似乎较小。我们得出结论,没有证据表明与OAB及其治疗反应相关的膀胱功能障碍存在重大性别差异,但在实验研究中,雌性动物的代表性严重不足。

相似文献

1
Sex and Gender Differences in the Pharmacology of the Overactive Urinary Bladder.膀胱过度活动症药理学中的性别差异
Handb Exp Pharmacol. 2023;282:57-74. doi: 10.1007/164_2023_667.
2
What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel.治疗女性膀胱过度活动症的各种疗法的短期获益和潜在危害有哪些?这是在欧洲泌尿外科学会、女性非神经原性下尿路症状指南专家组的支持下对证据进行的综述。
Eur Urol. 2023 Sep;84(3):302-312. doi: 10.1016/j.eururo.2023.05.014. Epub 2023 Jun 17.
3
Muscarinic receptor antagonists for overactive bladder.用于治疗膀胱过度活动症的毒蕈碱受体拮抗剂。
BJU Int. 2007 Nov;100(5):987-1006. doi: 10.1111/j.1464-410X.2007.07205.x.
4
Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.在接受 α 受体阻滞剂治疗下尿路症状的男性中,对于有残余储尿症状且疑似膀胱过度活动症的患者,加用非索罗定。
BJU Int. 2012 Jun;109(12):1831-40. doi: 10.1111/j.1464-410X.2011.10624.x. Epub 2011 Oct 3.
5
Intravesical botulinum-A toxin in children with refractory non-neurogenic overactive bladder.膀胱内注射肉毒杆菌毒素 A 治疗难治性非神经源性逼尿肌过度活动症患儿。
J Pediatr Urol. 2022 Jun;18(3):351.e1-351.e8. doi: 10.1016/j.jpurol.2022.02.007. Epub 2022 Feb 18.
6
The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS.在英国和瑞典,过度膀胱活动症对精神健康、工作生产力和健康相关生活质量的影响:EpiLUTS 的结果。
BJU Int. 2011 Nov;108(9):1459-71. doi: 10.1111/j.1464-410X.2010.10013.x. Epub 2011 Mar 3.
7
[The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].[膀胱过度活动症(OAB)药物治疗的新时代:米拉贝隆——一种新型选择性β3受体激动剂]
Ginekol Pol. 2014 Mar;85(3):214-9. doi: 10.17772/gp/1716.
8
OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.肉毒杆菌毒素 A 100U 显著改善伴有尿急和尿失禁的膀胱过度活动症患者的所有特发性膀胱过度活动症症状和生活质量:一项随机、双盲、安慰剂对照试验。
Eur Urol. 2013 Aug;64(2):249-56. doi: 10.1016/j.eururo.2013.04.001. Epub 2013 Apr 10.
9
Impact of Overactive Bladder-Wet Syndrome on Female Sexual Function: A Systematic Review and Meta-Analysis.过度活跃膀胱-湿综合征对女性性功能的影响:系统评价和荟萃分析。
Sex Med Rev. 2019 Oct;7(4):565-574. doi: 10.1016/j.sxmr.2019.05.002. Epub 2019 Jul 17.
10
Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men.超越抗毒蕈碱药物:男性膀胱过度活动症管理的药理学和介入治疗选择综述。
Eur Urol. 2021 Apr;79(4):492-504. doi: 10.1016/j.eururo.2020.12.032. Epub 2021 Jan 2.

引用本文的文献

1
Genetic Variation in , , and Alters the Pharmacokinetics and Safety of Mirabegron.、、和基因变异改变米拉贝隆的药代动力学和安全性。
Pharmaceutics. 2024 Aug 17;16(8):1077. doi: 10.3390/pharmaceutics16081077.
2
Long-term follow-up of TREK-1 KO mice reveals the development of bladder hypertrophy and impaired bladder smooth muscle contractility with age.TREK-1 KO 小鼠的长期随访结果显示,随着年龄的增长,其膀胱会出现肥大,膀胱平滑肌收缩功能受损。
Am J Physiol Renal Physiol. 2024 Jun 1;326(6):F957-F970. doi: 10.1152/ajprenal.00382.2023. Epub 2024 Apr 11.

本文引用的文献

1
Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders.当前和新兴的尿失禁及相关疾病的药理学靶点和治疗方法。
Pharmacol Rev. 2023 Jul;75(4):554-674. doi: 10.1124/pharmrev.121.000523. Epub 2023 Mar 14.
2
Analysis of changes in the pathophysiology of nocturia according to the number of nocturia episode, age, and gender using frequency volume charts: A retrospective observational study.基于夜间排尿次数、年龄和性别使用频率体积图表分析夜间多尿症的病理生理学变化:一项回顾性观察研究。
Medicine (Baltimore). 2022 Oct 28;101(43):e31295. doi: 10.1097/MD.0000000000031295.
3
Analysis of 16 studies in nine rodent models does not support the hypothesis that diabetic polyuria is a main reason of urinary bladder enlargement.
对九个啮齿动物模型中的16项研究进行分析后,并不支持糖尿病性多尿是膀胱增大主要原因这一假说。
Front Physiol. 2022 Aug 8;13:923555. doi: 10.3389/fphys.2022.923555. eCollection 2022.
4
What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine.对于摆脱膀胱过度活动症症状的期望有多现实?普罗苇因非介入性研究的经验。
Adv Ther. 2022 Jun;39(6):2489-2501. doi: 10.1007/s12325-022-02114-4. Epub 2022 Mar 24.
5
The Prevalence of Nocturnal Polyuria in the United States: Results from the Epidemiology of Nocturnal Polyuria Study.美国夜间多尿症的流行情况:来自夜间多尿症研究的流行病学结果。
Eur Urol Focus. 2022 Sep;8(5):1415-1423. doi: 10.1016/j.euf.2021.12.016. Epub 2022 Jan 14.
6
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors.《2021/22药理学简明指南:G蛋白偶联受体》
Br J Pharmacol. 2021 Oct;178 Suppl 1:S27-S156. doi: 10.1111/bph.15538.
7
Prevalence of nocturia among community-dwelling adults: a population-based study in Malaysia.社区成年人夜尿症的患病率:马来西亚一项基于人群的研究。
BMC Urol. 2021 Jun 29;21(1):95. doi: 10.1186/s12894-021-00860-1.
8
Factors Associated with Decisions for Initial Dosing, Up-Titration of Propiverine and Treatment Outcomes in Overactive Bladder Syndrome Patients in a Non-Interventional Setting.非干预性环境下膀胱过度活动症患者初始剂量决策、丙哌维林滴定增量及治疗结果的相关因素
J Clin Med. 2021 Jan 15;10(2):311. doi: 10.3390/jcm10020311.
9
Predictors of Poor Response and Adverse Events Following Botulinum Toxin A for Refractory Idiopathic Overactive Bladder: A Systematic Review.肉毒杆菌毒素 A 治疗难治性特发性过度活动膀胱不良反应和疗效不佳的预测因素:系统评价。
Eur Urol Focus. 2021 Nov;7(6):1448-1467. doi: 10.1016/j.euf.2020.06.013. Epub 2020 Jun 29.
10
Management of Urinary Incontinence With Underactive Bladder: A Review.膀胱活动低下型尿失禁的管理:综述
Int Neurourol J. 2020 Jun;24(2):111-117. doi: 10.5213/inj.2040076.038. Epub 2020 Jun 30.